Journal Article
. 2019 Dec;21(1).
doi: 10.1016/S1470-2045(19)30689-8.

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

Peter Schmid 1 Hope S Rugo 2 Sylvia Adams 3 Andreas Schneeweiss 4 Carlos H Barrios 5 Hiroji Iwata 6 Véronique Diéras 7 Volkmar Henschel 8 Luciana Molinero 9 Stephen Y Chui 9 Vidya Maiya 9 Amreen Husain 8 Eric P Winer 10 Sherene Loi 11 Leisha A Emens 12 IMpassion130 Investigators  
  • PMID: 31786121
  •     48 citations


Background: Immunotherapy in combination with chemotherapy has shown promising efficacy across many different tumour types. We report the prespecified second interim overall survival analysis of the phase 3 IMpassion130 study assessing the efficacy and safety of atezolizumab plus nab-paclitaxel in patients with unresectable, locally advanced or metastatic triple-negative breast cancer.

Methods: In this randomised, placebo-controlled, double-blind, phase 3 trial, done in 246 academic centres and community oncology practices in 41 countries, patients aged 18 years or older, with previously untreated, histologically documented, locally advanced or metastatic triple-negative breast cancer, and Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible. Patients were randomly assigned (1:1) using a permuted block method (block size of four) and an interactive voice-web response system. Randomisation was stratified by previous taxane use, liver metastases, and PD-L1 expression on tumour-infiltrating immune cells. Patients received atezolizumab 840 mg or matching placebo intravenously on day 1 and day 15 of every 28-day cycle and nab-paclitaxel 100 mg/m2 of body surface area intravenously on days 1, 8, and 15 until progression or unacceptable toxicity. Investigators, patients, and the funder were masked to treatment assignment. Coprimary endpoints were investigator-assessed progression-free survival per Response Evaluation Criteria in Solid Tumors version 1.1 and overall survival, assessed in the intention-to-treat population and in patients with PD-L1 immune cell-positive tumours (tumours with ≥1% PD-L1 expression). The final progression-free survival results were previously reported at the first interim overall survival analysis. The prespecified statistical testing hierarchy meant that overall survival in the subgroup of PD-L1 immune cell-positive patients could only be formally tested if overall survival was significantly different between the treatment groups in the intention-to-treat population. This study is registered with, NCT02425891.

Findings: Between June 23, 2015, and May 24, 2017, 902 patients were enrolled, of whom 451 were randomly assigned to receive atezolizumab plus nab-paclitaxel and 451 were assigned to receive placebo plus nab-paclitaxel (the intention-to-treat population). Six patients from each group did not receive treatment. At the second interim analysis (data cutoff Jan 2, 2019), median follow-up was 18·5 months (IQR 9·6-22·8) in the atezolizumab group and 17·5 months (8·4-22·4) in the placebo group. Median overall survival in the intention-to-treat patients was 21·0 months (95% CI 19·0-22·6) with atezolizumab and 18·7 months (16·9-20·3) with placebo (stratified hazard ratio [HR] 0·86, 95% CI 0·72-1·02, p=0·078). In the exploratory overall survival analysis in patients with PD-L1 immune cell-positive tumours, median overall survival was 25·0 months (95% CI 19·6-30·7) with atezolizumab versus 18·0 months (13·6-20·1) with placebo (stratified HR 0·71, 0·54-0·94]). As of Sept 3, 2018 (the date up to which updated safety data were available), the most common grade 3-4 adverse events were neutropenia (38 [8%] of 453 patients in the atezolizumab group vs 36 [8%] of 437 patients in the placebo group), peripheral neuropathy (25 [6%] vs 12 [3%]), decreased neutrophil count (22 [5%] vs 16 [4%]), and fatigue (17 [4%] vs 15 [3%]). Treatment-related deaths occurred in two (<1%) patients in the atezolizumab group (autoimmune hepatitis related to atezolizumab [n=1] and septic shock related to nab-paclitaxel [n=1]) and one (<1%) patient in the placebo group (hepatic failure). No new treatment-related deaths have been reported since the primary clinical data cutoff date (April 17, 2018).

Interpretation: Consistent with the first interim analysis, this second interim overall survival analysis of IMpassion130 indicates no significant difference in overall survival between the treatment groups in the intention-to-treat population but suggests a clinically meaningful overall survival benefit with atezolizumab plus nab-paclitaxel in patients with PD-L1 immune cell-positive disease. However, this positive result could not be formally tested due to the prespecified statistical testing hierarchy. For patients with PD-L1 immune cell-positive metastatic triple-negative breast cancer, atezolizumab plus nab-paclitaxel is an important therapeutic option in a disease with high unmet need.

Funding: F Hoffmann-La Roche and Genentech.

Oncolytic vesicular stomatitis virus-based cellular vaccine improves triple-negative breast cancer outcome by enhancing natural killer and CD8+ T-cell functionality.
Seyedeh-Raheleh Niavarani, Christine Lawson, +2 authors, Lee-Hwa Tai.
J Immunother Cancer, 2020 Mar 18; 8(1). PMID: 32179632    Free PMC article.
Lessons learned at SABCS 2019 and to-dos from immunotherapy in breast cancer.
Daniel Eiger, Mariana Brandão, Evandro de Azambuja.
ESMO Open, 2020 Mar 20; 5(2). PMID: 32188717    Free PMC article.
Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer.
Connie Kang, Yahiya Y Syed.
Drugs, 2020 Apr 06; 80(6). PMID: 32248356
Update Breast Cancer 2020 Part 2 - Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics.
Diana Lüftner, Andreas Schneeweiss, +16 authors, Michael P Lux.
Geburtshilfe Frauenheilkd, 2020 Apr 24; 80(4). PMID: 32322108    Free PMC article.
Molecular subtypes and precision treatment of triple-negative breast cancer.
Shen Zhao, Wen-Jia Zuo, Zhi-Ming Shao, Yi-Zhou Jiang.
Ann Transl Med, 2020 May 13; 8(7). PMID: 32395543    Free PMC article.
Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes.
Anna Diana, Francesca Carlino, +5 authors, Michele Orditura.
Cancers (Basel), 2020 Apr 03; 12(4). PMID: 32235297    Free PMC article.
Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
Jieqiong Liu, Qiang Liu, +10 authors, Erwei Song.
J Immunother Cancer, 2020 May 26; 8(1). PMID: 32448804    Free PMC article.
ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer.
J A Kyte, A Røssevold, R S Falk, B Naume.
J Transl Med, 2020 Jun 25; 18(1). PMID: 32576225    Free PMC article.
Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer.
Lee Cheng Phua, Soo Chin Lee, Kwong Ng, Mohamed Ismail Abdul Aziz.
BMC Health Serv Res, 2020 Jun 26; 20(1). PMID: 32580722    Free PMC article.
A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns.
Anna-Karin Tzikas, Szilard Nemes, Barbro K Linderholm.
Breast Cancer Res Treat, 2020 Jun 12; 182(3). PMID: 32524352    Free PMC article.
Breast Cancer in Patients 80 Years-Old and Older.
Aaron Bertolo, Christopher Rosso, Ioannis A Voutsadakis.
Eur J Breast Health, 2020 Jul 14; 16(3). PMID: 32656522    Free PMC article.
Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives.
Stefania Cocco, Michela Piezzo, +7 authors, Michelino de Laurentiis.
Int J Mol Sci, 2020 Jul 02; 21(13). PMID: 32605126    Free PMC article.
The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy.
Andrea Botticelli, Alessio Cirillo, +18 authors, Paolo Marchetti.
Vaccines (Basel), 2020 May 02; 8(2). PMID: 32353934    Free PMC article.
Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer.
Kabir A Khan, José L Ponce de Léon, +6 authors, Robert S Kerbel.
NPJ Breast Cancer, 2020 Jul 25; 6. PMID: 32704531    Free PMC article.
Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer.
Aitziber Buqué, Norma Bloy, +27 authors, Lorenzo Galluzzi.
Nat Commun, 2020 Aug 01; 11(1). PMID: 32732875    Free PMC article.
Immune parameters associated with survival in metaplastic breast cancer.
Xue Chao, Lili Liu, +6 authors, Jingping Yun.
Breast Cancer Res, 2020 Aug 20; 22(1). PMID: 32811533    Free PMC article.
Lack of access to CDK4/6 inhibitors for premenopausal patients with metastatic breast cancer in Brazil: estimation of the number of premature deaths.
Tomás Reinert, Rodrigo Pellegrini, Carlos Henrique Barrios.
Ecancermedicalscience, 2020 Aug 31; 14. PMID: 32863875    Free PMC article.
The stabilization of PD-L1 by the endoplasmic reticulum stress protein GRP78 in triple-negative breast cancer.
Cheng-Wei Chou, Ri-Yao Yang, +7 authors, Mien-Chie Hung.
Am J Cancer Res, 2020 Sep 10; 10(8). PMID: 32905506    Free PMC article.
Association of sonographic features and molecular subtypes in predicting breast cancer disease outcomes.
Haoyu Wang, Jiejie Yao, +3 authors, Kunwei Shen.
Cancer Med, 2020 Jul 14; 9(17). PMID: 32657039    Free PMC article.
Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide.
Adam C Mirando, Akash Patil, +6 authors, Aleksander S Popel.
Oncoimmunology, 2020 Sep 15; 9(1). PMID: 32923118    Free PMC article.
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).
F Cardoso, S Paluch-Shimon, +42 authors, E P Winer.
Ann Oncol, 2020 Sep 27; 31(12). PMID: 32979513    Free PMC article.
Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer.
Katia Khoury, Antoinette R Tan, +10 authors, Filipa Lynce.
Front Oncol, 2020 Sep 29; 10. PMID: 32983983    Free PMC article.
Chloride intracellular channel protein 2: prognostic marker and correlation with PD-1/PD-L1 in breast cancer.
Tao Xu, Zhi Wang, +3 authors, Xingrui Li.
Aging (Albany NY), 2020 Sep 12; 12(17). PMID: 32915772    Free PMC article.
Immune Checkpoint Blockade Improves Chemotherapy in the PyMT Mammary Carcinoma Mouse Model.
Evelyn Sirait-Fischer, Catherine Olesch, +6 authors, Andreas Weigert.
Front Oncol, 2020 Oct 06; 10. PMID: 33014872    Free PMC article.
Blockade of CCL2 expression overcomes intrinsic PD-1/PD-L1 inhibitor-resistance in transglutaminase 2-induced PD-L1 positive triple negative breast cancer.
Junyoung Choi, Hee Jin Lee, +15 authors, Dae Ho Lee.
Am J Cancer Res, 2020 Oct 13; 10(9). PMID: 33042623    Free PMC article.
FBI-1 enhanced the resistance of triple-negative breast cancer cells to chemotherapeutic agents via the miR-30c/PXR axis.
Hua Yang, Lili Ren, +10 authors, Guanghai Dai.
Cell Death Dis, 2020 Oct 15; 11(10). PMID: 33051436    Free PMC article.
Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer.
Jinhong Shi, Feiqi Liu, Yanqiu Song.
Cancer Manag Res, 2020 Oct 17; 12. PMID: 33061626    Free PMC article.
Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field.
Maximilian Marhold, Thais Topakian, +16 authors, Wolfgang Lamm.
ESMO Open, 2020 Oct 15; 5(5). PMID: 33051192    Free PMC article.
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies.
Antonio Marra, Dario Trapani, +2 authors, Giuseppe Curigliano.
NPJ Breast Cancer, 2020 Oct 23; 6. PMID: 33088912    Free PMC article.
Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.
Gagan K Gupta, Amber L Collier, +13 authors, Amy H Tang.
Cancers (Basel), 2020 Aug 28; 12(9). PMID: 32846967    Free PMC article.
Beyond Chemotherapies: Recent Strategies in Breast Cancer Treatment.
Arthur Foulon, Pierrick Theret, Lise Rodat-Despoix, Philippe Kischel.
Cancers (Basel), 2020 Sep 20; 12(9). PMID: 32947780    Free PMC article.
Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors.
David Bomze, Nethanel Asher, +4 authors, Tomer Meirson.
JAMA Netw Open, 2020 Oct 24; 3(10). PMID: 33095247    Free PMC article.
Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists.
Alice Y Ho, Jean L Wright, +19 authors, Gaorav P Gupta.
Int J Radiat Oncol Biol Phys, 2020 May 18; 108(1). PMID: 32417409    Free PMC article.
Identification and validation of a combined hypoxia and immune index for triple-negative breast cancer.
Shaoquan Zheng, Yutian Zou, +6 authors, Xiaoming Xie.
Mol Oncol, 2020 Jun 11;. PMID: 32521117    Free PMC article.
Immune-Activated Regional Lymph Nodes Predict Favorable Survival in Early-Stage Triple-Negative Breast Cancer.
Yi-Yu Chen, Jing-Yu Ge, Ding Ma, Ke-Da Yu.
Front Oncol, 2020 Nov 10; 10. PMID: 33163401    Free PMC article.
When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report.
Dimitrios C Ziogas, Aikaterini Gkoufa, +4 authors, Helen Gogas.
J Immunother Cancer, 2020 Nov 05; 8(2). PMID: 33144335    Free PMC article.
EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
Alexander Ring, Pushpinder Kaur, Julie E Lang.
BMC Cancer, 2020 Nov 11; 20(1). PMID: 33167919    Free PMC article.
Triple‑negative breast cancer therapy: Current and future perspectives (Review).
Kwang-Ai Won, Charles Spruck.
Int J Oncol, 2020 Nov 12; 57(6). PMID: 33174058    Free PMC article.
Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials.
Carmen Criscitiello, Antonio Marra, +4 authors, Giuseppe Curigliano.
Oncologist, 2020 Aug 14;. PMID: 32785940    Free PMC article.
Digital Pathology Analysis Quantifies Spatial Heterogeneity of CD3, CD4, CD8, CD20, and FoxP3 Immune Markers in Triple-Negative Breast Cancer.
Haoyang Mi, Chang Gong, +7 authors, Aleksander S Popel.
Front Physiol, 2020 Nov 17; 11. PMID: 33192595    Free PMC article.
Opportunities for Antigen Discovery in Metastatic Breast Cancer.
Ashwani K Sood, Michael Nemeth, +2 authors, Shipra Gandhi.
Front Immunol, 2020 Nov 17; 11. PMID: 33193348    Free PMC article.
Genomic Profiling Comparison of Germline BRCA and Non-BRCA Carriers Reveals CCNE1 Amplification as a Risk Factor for Non-BRCA Carriers in Patients With Triple-Negative Breast Cancer.
Xin Huang, Di Shao, +9 authors, Qiang Sun.
Front Oncol, 2020 Nov 17; 10. PMID: 33194720    Free PMC article.
Clinical Data on Immunotherapy in Breast Cancer.
Julia Caroline Radosa, Lisa Stotz, +3 authors, Marc Philipp Radosa.
Breast Care (Basel), 2020 Nov 24; 15(5). PMID: 33223989    Free PMC article.
Understanding PD-L1 Testing in Breast Cancer: A Practical Approach.
Ramona Erber, Arndt Hartmann.
Breast Care (Basel), 2020 Nov 24; 15(5). PMID: 33223991    Free PMC article.
Liquid Biopsies to Evaluate Immunogenicity of Gynecological/Breast Tumors: On the Way to Blood-Based Biomarkers for Immunotherapies.
Corinna Keup, Rainer Kimmig, Sabine Kasimir-Bauer.
Breast Care (Basel), 2020 Nov 24; 15(5). PMID: 33223990    Free PMC article.
Cancer-Associated Fibroblasts: Understanding Their Heterogeneity.
Kévin Louault, Rong-Rong Li, Yves A DeClerck.
Cancers (Basel), 2020 Oct 30; 12(11). PMID: 33114328    Free PMC article.
First line Immunotherapy for Non-Small Cell Lung Cancer.
Nicola J Nasser, Miguel Gorenberg, Abed Agbarya.
Pharmaceuticals (Basel), 2020 Nov 12; 13(11). PMID: 33171686    Free PMC article.
Prevention, Detection, and Management of Heart Failure in Patients Treated for Breast Cancer.
Agneta Månsson Broberg, Jürgen Geisler, +8 authors, Geeta Gulati.
Curr Heart Fail Rep, 2020 Sep 27; 17(6). PMID: 32979150    Free PMC article.